Advertisement

Annals of Surgical Oncology

, Volume 21, Issue 9, pp 3084–3089 | Cite as

γ-Glutamyltranspeptidase is a Prognostic Marker of Survival and Recurrence in Radiofrequency-Ablation Treatment of Hepatocellular Carcinoma

  • Hui Ma
  • Lan Zhang
  • Bei Tang
  • Yan Wang
  • Rongxin Chen
  • Boheng Zhang
  • Yi Chen
  • Ningling Ge
  • Yanhong Wang
  • Yuhong Gan
  • Shenglong Ye
  • Zhenggang Ren
Hepatobiliary Tumors

Abstract

Purpose

Serum γ-glutamyltranspeptidase (GGT) level, which is often elevated in hepatocellular carcinoma (HCC), has now been found to be an oxidative stress marker which correlates with inflammation in the extracellular hepatic microenvironment. The aim of this study was to investigate the prognostic significance of GGT serum levels in patients undergoing radiofrequency ablation (RFA) therapy for the treatment of HCC.

Methods

This retrospective study included 254 patients with small liver cancer (tumor of ≤5 cm in diameter and nodule of ≤3 cm) who had been treated with RFA. Baseline serum GGT was examined before therapy, and overall survival (OS) and recurrence-free survival were evaluated by the Kaplan–Meier method. Univariate and multivariate analyses were used to analyze the significance of GGT and other serum markers as prognostic factors.

Results

After a median follow-up of 27 months, 51 patients had died and 123 had hepatic recurrence. After treatment with RFA, HCC patients with elevated GGT had a shorter OS versus those with normal GGT level (p = 0.001); they also had higher recurrence (p = 0.001). On multivariate analysis, albumin (p = 0.003), GGT (p = 0.035), and tumor size (p = 0.027) were independent risk factors for survival, and GGT (p = 0.010) and tumor size (p = 0.026) were significant risk factors for recurrence.

Conclusions

Serum GGT is a convenient prognostic biomarker related to OS and recurrence in HCC patients undergoing RFA treatment.

Keywords

Overall Survival Tace 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

This study was supported by the National Clinical Key Special Subject of China (Grant 81172275) and the National Natural Science Foundation of China (Grant 21272565).

Conflicts of interest

Hui Ma, Lan Zhang, Bei Tang, Yan Wang, Rongxin Chen, Boheng Zhang, Yi Chen, Ningling Ge, Yanhong Wang, Yuhong Gan, Shenglong Ye, and Zhenggang Ren declare that they have no conflicts of interest.

Supplementary material

10434_2014_3724_MOESM1_ESM.docx (16 kb)
Supplementary material 1 (DOCX 16 kb)

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:68–90.CrossRefGoogle Scholar
  2. 2.
    Padhya KT, Marrero JA, Singal AG. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2013;29:285–92.PubMedCrossRefGoogle Scholar
  3. 3.
    Genco C, Cabibbo G, Maida M, Brancatelli G, Galia M, Alessi N, et al. Treatment of hepatocellular carcinoma: present and future. Expert Rev Anticanc. 2013;13:469–79.CrossRefGoogle Scholar
  4. 4.
    Hung HH, Chiou YY, Hsia CY, Su CW, Chou YH, Chiang JH, et al. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol. 2011;9:79–86.PubMedCrossRefGoogle Scholar
  5. 5.
    Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47:82–89.PubMedCrossRefGoogle Scholar
  6. 6.
    Ikeda Y, Taniguchi N. Gene expression of gamma-glutamyltranspeptidase. Methods Enzymol. 2005;401:408–25.PubMedCrossRefGoogle Scholar
  7. 7.
    Zhang JB, Chen Y, Zhang B, Xie X, Zhang L, Ge N, et al. Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol. 2011;23:787–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Corti A, Franzini M, Paolicchi A, Pompella A. Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res. 2010;30:1169–82.PubMedGoogle Scholar
  9. 9.
    Silva IS, Ferraz ML, Perez RM, Lanzoni VP, Figueiredo VM, Silva AE. Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2004;19:314–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Guiu B, Deschamps F, Boulin M, Boige V, Malka D, Ducreux M, et al. Serum gamma-glutamyl-transferase independently predicts outcome after transarterial chemoembolization of hepatocellular carcinoma: external validation. Cardiovasc Intervent Radiol. 2012;35:1102–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Ju MJ, Qiu SJ, Fan J, Zhou J, Gao Q, Cai MY, et al. Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation. J Gastroenterol. 2009;44:635–42.PubMedCrossRefGoogle Scholar
  12. 12.
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Lau WY, Lai EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg. 2009;249:20–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, et al. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology. 2007;72:98–103.PubMedCrossRefGoogle Scholar
  15. 15.
    Guglielmi A, Ruaaenente A, Sandri M, Pachera S, Pedrazzani C, Tasselli S, et al. Radiofrequency ablation for hepatocellular carcinoma in cirrhotic patients: prognostic factors for survival. J Gastrointest Surg. 2007;11:143–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Xia F, Lai EC, Lau WY, Ma K, Li X, Bie P, et al. High serum hyaluronic acid and HBV viral load are main prognostic factors of local recurrence after complete radiofrequency ablation of hepatitis B-related small hepatocellular carcinoma. Ann Surg Oncol. 2012;19:1284–91.PubMedCrossRefGoogle Scholar
  17. 17.
    Pompella A, Tata VD, Paolicchi A, Zunino F. Expression of γ-glutamyltransferase in cancer cells and its significance in drug resistance. Biochem Pharmacol. 2006;71:231–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Hanahan D, Weiberg RA. Hallmarkers of cancer: the next generation. Cell. 2011;144:646–74.PubMedCrossRefGoogle Scholar
  19. 19.
    Tarao K, Takemiya S, Tamai S, Sugimasa Y, Ohkawa S, Akaike M, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatic C virus-associated cirrhosis and HCC. Cancer. 1997;79:688–94.PubMedCrossRefGoogle Scholar
  20. 20.
    Everhart JE, Wright EC. Association of γ-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV). Hepatology. 2013;57:1725–33.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Hui Ma
    • 1
  • Lan Zhang
    • 1
  • Bei Tang
    • 1
  • Yan Wang
    • 1
  • Rongxin Chen
    • 1
  • Boheng Zhang
    • 1
  • Yi Chen
    • 1
  • Ningling Ge
    • 1
  • Yanhong Wang
    • 1
  • Yuhong Gan
    • 1
  • Shenglong Ye
    • 1
  • Zhenggang Ren
    • 1
  1. 1.Liver Cancer Institute, Zhongshan HospitalFudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of EducationShanghaiChina

Personalised recommendations